Clinical evidence from aromatase-deficient males reveals an estrogen-dependent MetS phenotype characterized by dyslipidemia, ectopic fat deposition, and glucose intolerance, which is reversed by estrogen therapy [170]. This evidence concerns the gene CYP19A1 and metabolic syndrome.